Modelling systemic risk factors in cardiovascular disease using single-cell biology

The plasma of individuals with atherosclerosis contains cytokines that induce a pathogenic signaling cascade in immune cells. Saracatinib, a dual kinase inhibitor that targets the tyrosine kinases SRC and BCR-ABL, can prevent activation of this phospho-signaling pathway implicated in the pathogenesis of cardiovascular disease.